Seo Jeong Shin

Ms. Seo Jeong Shin

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Computer Methods and Programs in Biomedicine
Verified
Journal Article
Closed access
SSSeo Jeong Shin
Seo Jeong Shin
SYSeng Chan You
Seng Chan You
HJHokyun Jeon
Hokyun Jeon
JJJi Won Jung
Ji Won Jung
MAMin Ho An
Min Ho An
JRJin Roh
Jin Roh

26 March 2019 in Journal of Medical Internet Research
Verified
Journal Article
Open access
SSSeo Jeong Shin
Seo Jeong Shin
SYSeng Chan You
Seng Chan You
YPYu Rang Park
Yu Rang Park
JRJin Roh
Jin Roh
JKJang-Hee Kim
Jang-Hee Kim
Rae Woong ParkRae Woong Park
Rae Woong Park
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Clinical sequencing data should be shared so as to achieve the sufficient scale and diversity required for providing strong evidence toward improving patient care. A distributed research network (DRN) allows researchers to share this evidence rather than the patient-level data across centers, thereby avoiding privacy issues. The Observational Medical Outcomes Partnership (OMOP) common data model (CDM), currently used in DRNs, has low coverage of sequencing data and does not reflect the latest trend of precision medicine. Objective: The aim of this study was to develop and evaluate the feasibility of a genomic CDM (G-CDM), as an extension of the OMOP-CDM, for application of genomic data in clinical practice. Methods: Existing genomic data models and sequencing reports were reviewed to extend the OMOP-CDM to cover genomic data. Human Genome Organisation (HUGO) Gene Nomenclature Committee (HGNC) and Human Genome Variation Society (HGVS) nomenclature was adopted to standardize the terminology in the model. Sequencing data of 114 and 1060 patients with lung cancer were obtained from the Ajou University School of Medicine (AUSOM) database of Ajou University Hospital and The Cancer Genome Atlas (TCGA), respectively, which were transformed to a format appropriate for the G-CDM. The data were compared with respect to gene name, variant type, and actionable mutations. Results: The G-CDM was extended into four tables linked to tables of the OMOP-CDM. Upon comparison with TCGA data, a clinically actionable mutation, ‘p.Leu858Arg’, in the EGFR gene was 6.64-times more frequent in the AUSOM database, while the ‘p.Gly12Xaa’ mutation in the KRAS gene was 2.02-times more frequent in the TCGA dataset. The data-exploring tool GeneProfiler was further developed to conduct descriptive analyses automatically using the G-CDM, which provides the proportions of genes, variant types, and actionable mutations. GeneProfiler also allows for querying the specific gene name and HGVS nomenclature to calculate the proportion of patients with a given mutation. Conclusions: We developed the G-CDM for effective integration of genomic data with standardized clinical data allowing for data sharing across institutes. The feasibility of the G-CDM was validated by assessing the differences in data characteristics between two different genomic databases through the proposed data-exploring tool, GeneProfiler. The G-CDM may facilitate analyses of interoperating clinical and genomic datasets across multiple institutions, minimizing privacy issues and thereby enabling researchers to better understand the characteristics of patients and promote personalized medicine in clinical practice.

21 January 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
SLSeunghwa Lee
Seunghwa Lee
JPJungchan Park
Jungchan Park
Rae Woong ParkRae Woong Park
Rae Woong Park
SSSeo Jeong Shin
Seo Jeong Shin
JKJinseob Kim
Jinseob Kim
KYKwangmo Yang
Kwangmo Yang
Studies have reported conflicting results on the association between the use of renin-angiotensin-aldosterone system (RAAS) inhibitors and cancer development. We compared the incidence of cancer between patients using RAAS inhibitors and other antihypertensive drugs. This retrospective observational cohort study used data from seven hospitals in Korea that were converted for use in the Observational Medical Outcomes Partnership Common Data Model. A total of 166,071 patients on antihypertensive therapy across the databases of the seven hospitals were divided into two groups according to the use of RAAS inhibitors. The primary outcome was the occurrence of cancer. A total of 166,071 patients across the databases of the seven hospitals was included in the final analysis; 26,650 (16%) were in the RAAS inhibitors group and 139,421 (84%) in the other antihypertensive drugs group. The meta-analysis of the whole cohort showed a lower incidence of cancer occurrence in the RAAS inhibitor group (9.90 vs. 13.28 per 1000 person years; HR, 0.81; 95% confidence interval [CI], 0.75–0.88). After propensity-score matching, the RAAS inhibitor group consistently showed a lower incidence of cancer (9.90 vs. 13.28 per 1000 person years; HR, 0.86; 95% CI, 0.81–0.91). The patients using RAAS inhibitors showed a lower incidence of cancer compared with those using other antihypertensive drugs. These findings support the association between the use of RAAS inhibitors and cancer occurrence.

14 October 2021 in JMIR Medical Informatics
Verified
Journal Article
Open access
SSSeo Jeong Shin
Seo Jeong Shin
Jungchan ParkJungchan Park
Jungchan Park
SLSeunghwa Lee
Seunghwa Lee
KYKwangmo Yang
Kwangmo Yang
Rae Woong ParkRae Woong Park
Rae Woong Park
Background: Myocardial injury after noncardiac surgery (MINS) is associated with increased postoperative mortality, but the relevant perioperative factors that contribute to the mortality of patients with MINS have not been fully evaluated. Objective: To establish a comprehensive body of knowledge relating to patients with MINS, we researched the best performing predictive model based on machine learning algorithms. Methods: Using clinical data from 7629 patients with MINS from the clinical data warehouse, we evaluated 8 machine learning algorithms for accuracy, precision, recall, F1 score, area under the receiver operating characteristic (AUROC) curve, and area under the precision-recall curve to investigate the best model for predicting mortality. Feature importance and Shapley Additive Explanations values were analyzed to explain the role of each clinical factor in patients with MINS. Results: Extreme gradient boosting outperformed the other models. The model showed an AUROC of 0.923 (95% CI 0.916-0.930). The AUROC of the model did not decrease in the test data set (0.894, 95% CI 0.86-0.922; P=.06). Antiplatelet drugs prescription, elevated C-reactive protein level, and beta blocker prescription were associated with reduced 30-day mortality. Conclusions: Predicting the mortality of patients with MINS was shown to be feasible using machine learning. By analyzing the impact of predictors, markers that should be cautiously monitored by clinicians may be identified.

23 October 2026 in Korean Circulation Journal
Verified
Journal Article
Open access
PDF file
JKJaewon Khil
Jaewon Khil
SSSojung Shin
Sojung Shin
SSSeo Jeong Shin
Seo Jeong Shin
JLJaeyong Lee
Jaeyong Lee
MCMinsung Cho
Minsung Cho
HKHyeon Chang Kim
Hyeon Chang Kim
Khil J, et al. Korean Circ J. 2027 ;57:e40. https://doi.org/10.4070/kcj.2026.0060

23 August 2026 in Clinical and Translational Science
Verified
Journal Article
Open access
PDF file
HLHaeyoung Lee
Haeyoung Lee
EPEun‐Gee Park
Eun‐Gee Park
HYHyeon-Jong Yang
Hyeon-Jong Yang
YSYoung-Gyun Seo
Young-Gyun Seo
DKDong Yoon Kang
Dong Yoon Kang
SSSoo Jung Sohn
Soo Jung Sohn
In July 2025, the Food and Drug Administration (FDA) warned of significant weight loss among young children receiving stimulants for attention‐deficit hyperactivity disorder. However, real‐world evidence on the magnitude and prevalence of stimulant‐associated weight loss remains limited. This study evaluated short‐term weight changes after methylphenidate initiation among youth aged 3–18 years using the Medical record Observation and Assessment of drug safety Common Data Model (MOA CDM) in Korea. We conducted a retrospective study using electronic health record‐based MOA CDM data from January 2008 to December 2024. The cohort included individuals aged 3–18 years with at least one methylphenidate prescription and had available weight measurements. The index date was defined as the first prescription date. Individuals without weight data within 45 days before or 90 days after the index date were excluded. Outcomes included changes in body weight (kg) and weight percentile, and the proportion having a ≥ 10‐percentile decline. Weight percentiles were calculated using the 2017 Korean National Growth Charts for Children and Adolescents. A total of 2087 youths from 17 nationwide hospitals were included; 68.71% were male, and 58.12% were aged 6–10 years. Within 3 months, mean body weight decreased by −0.33 kg (95% confidence interval [CI], −0.44 to −0.22) and mean weight percentile decreased by −2.49 percentiles (95% CI, −2.83 to −2.15). Overall, 21.57% had a ≥ 10 percentile decline, with larger reductions among pre‐school‐aged children (28.57%). Our findings underscores the importance of growth monitoring during treatment initiation.